ResearcherUniversity of Colorado AnschutzActive in the last 2 years

Sarah J. Hartman

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0008-8092-1673; OpenAlex author ID A5056860889. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 8

Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper

Papers 2

Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tumor organoid library (PTOL). Co-author DOI 10.1371/journal.pone.0298808 ↗
WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.642328 ↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Alexis Diane Leal · 2 shared papers, 2021–2024 · strength 0.29
- Paper Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tum… DOI 10.1371/journal.pone.0298808 ↗
- Paper WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ducta… DOI 10.3389/fonc.2021.642328 ↗
Christopher Hanyoung Lieu · 2 shared papers, 2021–2024 · strength 0.29
- Paper Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tum… DOI 10.1371/journal.pone.0298808 ↗
- Paper WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ducta… DOI 10.3389/fonc.2021.642328 ↗
Todd M. Pitts · 2 shared papers, 2021–2024 · strength 0.29
- Paper Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tum… DOI 10.1371/journal.pone.0298808 ↗
- Paper WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ducta… DOI 10.3389/fonc.2021.642328 ↗
Wells A. Messersmith · 2 shared papers, 2021–2024 · strength 0.29
- Paper Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tum… DOI 10.1371/journal.pone.0298808 ↗
- Paper WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ducta… DOI 10.3389/fonc.2021.642328 ↗
John J. Arcaroli · 1 shared paper, 2024 · strength 0.18
- Paper Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tum… DOI 10.1371/journal.pone.0298808 ↗
Robert William Lentz · 1 shared paper, 2024 · strength 0.18
- Paper Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tum… DOI 10.1371/journal.pone.0298808 ↗
Hayley J Hawkins · 1 shared paper, 2024 · strength 0.18
- Paper Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tum… DOI 10.1371/journal.pone.0298808 ↗
Sarah Lindsey Davis · 1 shared paper, 2021 · strength 0.12
- Paper WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ducta… DOI 10.3389/fonc.2021.642328 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.